FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to inhibiting or decreasing a level of inflammation mediator release from inflammatory cells by suppressing a mechanism associated with inflammation mediator release from inflammatory cell granules by using the versions of MANS peptide.
EFFECT: invention refers to an endocellular signal transmission mechanism which allows detecting a number of new endocellular targets for the pharmacological treatment of disorders associated with inflammation mediator secretion from inflammatory cell vesicles.
25 cl, 15 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF REGULATING INFLAMMATION MEDIATORS AND PEPTIDES USED IN THEM | 2007 |
|
RU2429004C2 |
| MUCIN HYPERSECRETION INHIBITORS AND METHODS OF APPLICATION THEREOF | 2006 |
|
RU2423379C2 |
| METASTASIS INHIBITORS | 2014 |
|
RU2681213C2 |
| PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLAMMATORY CYTOKINES | 2019 |
|
RU2816868C2 |
| ANTIBACTERIAL PEPTIDES | 2007 |
|
RU2468033C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| TREATMENT OF INFLAMMATION, AUTOIMMUNE, AND NEURODEGENERATIVE DISORDERS WITH IMMUNOSUPPRESSIVE TAT DERIVATIVE POLYPEPTIDES | 2013 |
|
RU2653754C2 |
| PEPTIDES, DETACHED FROM HUMAN LACTOFERRIN, AND USE THEREOF | 2012 |
|
RU2593757C2 |
| ANTIBODIES AGAINST G-CSFR AND USE THEREOF | 2012 |
|
RU2605595C2 |
